TY  - JOUR
A1  - Voß, Martin
A1  - Wenger-Alakmeh, Katharina Johanna
A1  - Mettenheim, Nina von
A1  - Bojunga, Jörg
A1  - Vetter, Manuela
A1  - Diehl, Bianca
A1  - Franz, Kea
A1  - Gerlach, Rüdiger
A1  - Ronellenfitsch, Michael Wilfried
A1  - Harter, Patrick Nikolaus
A1  - Hattingen, Elke
A1  - Steinbach, Joachim Peter
A1  - Rödel, Claus
A1  - Rieger, Johannes
T1  - Short-term fasting in glioma patients: analysis of diet diaries and metabolic parameters of the ERGO2 trial
T2  - European journal of nutrition
N2  - Purpose: The prospective, randomized ERGO2 trial investigated the effect of calorie-restricted ketogenic diet and intermittent fasting (KD-IF) on re-irradiation for recurrent brain tumors. The study did not meet its primary endpoint of improved progression-free survival in comparison to standard diet (SD). We here report the results of the quality of life/neurocognition and a detailed analysis of the diet diaries. Methods: 50 patients were randomized 1:1 to re-irradiation combined with either SD or KD-IF. The KD-IF schedule included 3 days of ketogenic diet (KD: 21–23 kcal/kg/d, carbohydrate intake limited to 50 g/d), followed by 3 days of fasting and again 3 days of KD. Follow-up included examination of cognition, quality of life and serum samples. Results: The 20 patients who completed KD-IF met the prespecified goals for calorie and carbohydrate restriction. Substantial decreases in leptin and insulin and an increase in uric acid were observed. The SD group, of note, had a lower calorie intake than expected (21 kcal/kg/d instead of 30 kcal/kg/d). Neither quality of life nor cognition were affected by the diet. Low glucose emerged as a significant prognostic parameter in a best responder analysis. Conclusion: The strict caloric goals of the ERGO2 trial were tolerated well by patients with recurrent brain cancer. The short diet schedule led to significant metabolic changes with low glucose emerging as a candidate marker of better prognosis. The unexpected lower calorie intake of the control group complicates the interpretation of the results. Clinicaltrials.gov number: NCT01754350; Registration: 21.12.2012.
KW  - Glioblastoma
KW  - Radiation
KW  - Ketogenic diet
KW  - Fasting
KW  - Glucose
KW  - Leptin
Y1  - 2021
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/63759
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-637598
SN  - 1436-6215
N1  - Open Access funding enabled and organized by Projekt DEAL. The Senckenberg Institute of Neurooncology is supported by the Senckenberg Foundation. This trial was funded by the investigator-initiated trial (IIT) program of the University Cancer Center Frankfurt (UCT). Ketogenic drinks were supplied by Tavarlin® without costs. Neither the UCT nor Tavarlin® had any involvement in the clinical trial itself or the writing of the report.
N1  - Version of Record: http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:hebis:30:3-627941
N1  - Early View: Online Version before inclusion in an issue.
VL  - 2021
IS  - online version before inclusion in an issue
PB  - Steinkopff
CY  - Darmstadt
ER  -